Precision BioSciences (NASDAQ:DTIL) reported a sharp swing to profitability in its final quarter of 2025, a result primarily driven by the recognition of deferred revenue from its heavyweight partnerships in the genome-editing space.
The Durham, North Carolina-based biotechnology firm posted net income of $20.1 million, or $1.05 per share, for the fourth quarter.
On an adjusted basis, excluding one-time gains and non-cash items, earnings stood at $0.36 per share, significantly outperforming the consensus loss predicted by analysts.
The quarterly surge was fueled by $34.2 million in revenue, largely attributed to milestones within its ARCUS platform collaborations, including the conclusion of a hemoglobinopathy program with Novartis and licensing activity with Imugene.
Despite the strong finish to the year, the full-year 2025 results reflected the high costs of clinical-stage drug development.
Precision reported an annual loss of $45.7 million on total revenue of $34.3 million—highlighting that almost the entirety of the year's revenue was realized in the final three months.
The company’s strategic focus remains on its in vivo gene-editing pipeline.